<DOC>
	<DOCNO>NCT00411424</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability new medication ASK8007 , study whether beneficial effect joint inflammation patient rheumatoid arthritis .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy Study New Medication ASK8007 Treat Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>meet American Rheumatism Association ( ARA ) 1987 revise criterion classification RA ( also refer American College Rheumatology [ ACR ] criterion ) ; treat adequate dose ( discretion local physician ) either MTX leflunomide ( LEF ) sulfasalazine ( SS2 ) least 4 month prior baseline last 6 week baseline stable dose ; active polyarthritis ( i.e . active rheumatoid arthritis define detail protocol ) treat registered nonregistered investigational drug context clinical intervention study last 3 month baseline ; treat TNFÎ±blockers within certain period time ( defined medication ) baseline ; treat DMARD MTX , LEF SS2 last month baseline ; document evidence presence clinically severe , unstable , uncontrollable renal , hepatic , respiratory , hematological , genitourinary , cardiovascular , endocrine , neurological , psychiatric , medical illness would , opinion investigator , put patient safety risk mask measure efficacy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Randomized Control Trial</keyword>
	<keyword>Treatment outcome</keyword>
	<keyword>Monoclonal antibody</keyword>
</DOC>